IL1RAP and chronic myelogenous leukemia, BCR-ABL1 positive: In vivo data have shown that chimeric antigen receptor T (CAR-T) cells targeting IL1RAP may be a viable option to eliminate MRD/LSCs and ‘cure’ CML [61].